Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Solid BiosciencesSLDB +2.26%34 14-Day RSI is 56.60 as of Aug. 13, 2026. GuruFocus rates SLDB with a GF Score™ of 34/100. The stock has 2 warning signs investors should review. Among 1,416 Biotechnology companies, Solid Biosciences ranks worse than 56.21% on this metric.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.
Solid Biosciences 14-Day RSI Related Terms
SLDB vs MNPR, DSGN, CLYM: 14-Day RSI Comparison
For the Biotechnology subindustry, Solid Biosciences's 14-Day RSI, along with its competitors' market caps and 14-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Solid Biosciences 14-Day RSI vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Solid Biosciences's 14-Day RSI distribution charts can be found below:
* The bar in red indicates where Solid Biosciences's 14-Day RSI falls into.
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Solid Biosciences (SLDB) has a 14-Day RSI of 56.60 as of Aug. 13, 2026. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Solid Biosciences and its competitors. According to the industry distribution chart, Solid Biosciences ranks #796 out of 1416 companies in the Biotechnology industry, placing it in the top 56.2%.
Is Solid Biosciences' 14-Day RSI too high?
Solid Biosciences' current 14-Day RSI is 56.60. The Biotechnology industry median 14-Day RSI is 52.46. Solid Biosciences' value of 56.60 is 7.9% above this industry median. Based on the distribution chart, Solid Biosciences ranks #796 out of 1416 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Solid Biosciences has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Solid Biosciences' 14-Day RSI compare to MNPR and DSGN?
According to the Biotechnology industry distribution chart, Solid Biosciences ranks #796 out of 1416 companies for 14-Day RSI. This places Solid Biosciences in the lower half of its industry. The industry median 14-Day RSI is 52.46. Solid Biosciences' value of 56.60 is 7.9% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 14-Day RSI for a Biotechnology company?
The median 14-Day RSI among Biotechnology companies is 52.46, based on 1,416 companies in the industry. Companies in the top quartile (top 25%) have a 14-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 14-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Solid Biosciences's current 14-Day RSI of 56.60 is 7.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 14-Day RSI mean?
A high 14-Day RSI can signal that a stock is expensive relative to its fundamentals. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Solid Biosciences and its competitors. For the Biotechnology industry, the median 14-Day RSI is 52.46 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Solid Biosciences's current 14-Day RSI is 56.60. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Solid Biosciences stock overvalued right now?
Solid Biosciences (SLDB) has a current 14-Day RSI of 56.60. The current 14-Day RSI is 56.60 and 7.9% above the Biotechnology industry median of 52.46. Solid Biosciences' overall GF Score™ is 34/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 14-Day RSI calculated?
14-Day RSI is calculated from a company's financial statements. For Solid Biosciences (SLDB), the current 14-Day RSI is 56.60 as of Aug. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Solid Biosciences Inc is a life sciences company focused on advancing a portfolio of current and future gene therapy candidates, including SGT-003 for the treatment of Duchenne muscular dystrophy, SGT-212 for the treatment of Friedreich's ataxia, SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia, SGT-601 for the treatment of TNNT2-mediated dilated cardiomyopathy, and additional assets for the treatment of genetic cardiac and neuromuscular diseases. The majority of its current programs are designed to treat these diseases with gene transfer products. The company operates in a single segment, developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases.
34GF Score
Get the complete analysis for SLDB
14-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SLDB has been successfully added to your 
